#USA #Duluth #Bridge to Life #organ preservation #ILTS

Bridge to Life Announces Participation in ILTS 2026 Congress

Bridge to Life™ Ltd., globally recognized for its cutting-edge organ preservation solutions and perfusion technology, is set to participate in the upcoming International Liver Transplantation Society (ILTS) Congress 2026. This prestigious event will take place from May 6 to 9, 2026, in Geneva, Switzerland, where the company aims to share its latest research and innovations in liver transplantation.

The ILTS Congress is a significant gathering for liver transplant professionals, showcasing the latest advancements in surgical techniques, organ preservation strategies, and patient care. Bridge to Life will present twelve accepted abstracts, which include five oral presentations and seven poster presentations. Among these, a noteworthy presentation will feature the hypothermic oxygenated perfusion (HOPE) technique utilized with the VitaSmart™ system. This method has implications for liver transplants, particularly in pediatric cases and partial grafts.

Key Presentations

During the conference, a variety of topics related to organ preservation will be discussed. One of the highlighted presentations is titled "Donor Serum FMN Reflects Mitochondrial Injury and Predicts Outcomes After Liver Transplantation: A Metabolic Donor Signature of Graft Quality." This session will take place on May 7, 2026, and will be presented by Fatma Selin Yildirim from the Cleveland Clinic.

Another important presentation, conducted by Omer Faruk Karakaya, also from the Cleveland Clinic, will showcase the findings on how prolonged hypothermic oxygenated perfusion can preserve mitochondrial function in liver transplantation. This session emphasizes the flexibility and potential for improved outcomes in liver transplants, scheduled for the same day.

The poster presentations will also cover a range of innovative research topics, including advanced studies on the effectiveness of HOPE in donor livers and the microbiological assessments of perfusates before and after hypothermic oxygenated perfusion. Two of the notable posters presented will delve into the correlation between donor risk factors and predictive outcomes following liver transplantation, highlighting the evolving role of artificial intelligence and machine learning in the field.

Symposium Sponsorship

In addition to its presentations, Bridge to Life is sponsoring a symposium titled "The Future of Machine Perfusion: Combining Strategies, Optimizing Care, and Expanding Possibilities," scheduled for May 7 from 12:45 PM to 1:45 PM CEST. This session will feature expert speakers from top medical institutions who will discuss the integration of machine perfusion technologies and their implications for enhancing patient care and organ viability.

About Bridge to Life™ Ltd

Founded with a commitment to improve organ preservation and transplantation, Bridge to Life™ Ltd. offers high-quality products including Belzer UW®, EasiSlush®, and the pioneering VitaSmart™ system. The company prides itself on its focus on quality, innovation, and accessibility, working closely with leading transplant centers and organ procurement organizations worldwide. With its substantial contributions to the field of organ transplantation, Bridge to Life continues to set standards in organ preservation technology, ensuring better outcomes for patients and transplant teams alike.

As the countdown to the ILTS Congress 2026 begins, the anticipation for Bridge to Life's presentations and symposium highlights the company's commitment to innovation in organ transplantation and preservation practices.